A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal …
L Paz-Ares, JM Sanchez, A Garcia-Velasco… - Journal of Clinical …, 2006 - ascopubs.org
7020 Background: The EGFR TK inhibitor erlotinib is a standard treatment in previously
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …
ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive …
K Park, CM Tsai, M Ahn, CJ Yu, SW Kim… - 2012 - ascopubs.org
TPS7614 Background: First-line erlotinib (an EGFR tyrosine-kinase inhibitor) significantly
increased progression-free survival (PFS) vs chemotherapy in phase III trials of pts with …
increased progression-free survival (PFS) vs chemotherapy in phase III trials of pts with …
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
T Kobayashi, T Koizumi, T Agatsuma, M Yasuo… - Cancer chemotherapy …, 2012 - Springer
Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese …
7520 Background: The OPTIMAL study demonstrated significant superiority for E versus GC
in terms of progression-free survival (PFS), objective response rate, tolerability and quality of …
in terms of progression-free survival (PFS), objective response rate, tolerability and quality of …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer
Objectives In 2008, we initiated a prospective study to explore the frequency and predictive
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR …
Background This study evaluated whether an addition of bevacizumab to erlotinib improves
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
Erlotinib in the first-line treatment of non-small-cell lung cancer
M D'Arcangelo, F Cappuzzo - Expert review of anticancer therapy, 2013 - Taylor & Francis
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
GR Oxnard, VA Miller - Oncology, 2010 - search.proquest.com
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …